Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Inhibitors develop in many patients with hemophilia who receive recombinant factor VIII. Prophylaxis with emicizumab, an antibody that functionally replaces factor VIII in the clotting pathway, reduced the rate of bleeding events among patients with hemophilia with inhibitors.
Saved in:
Published in | The New England journal of medicine Vol. 377; no. 9; pp. 809 - 818 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Massachusetts Medical Society
31.08.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Inhibitors develop in many patients with hemophilia who receive recombinant factor VIII. Prophylaxis with emicizumab, an antibody that functionally replaces factor VIII in the clotting pathway, reduced the rate of bleeding events among patients with hemophilia with inhibitors. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa1703068 |